Alnylam Pharmaceuticals, Inc. (ALNY)
Nasdaq: ALNY · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2002
Grade6.8
◀ Past 7.0● Present 7.0▶ Future 6.3
Who owns Alnylam Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
4
Fmr LLC holds 11% of COMMON STOCK, as its SCHEDULE 13G/A filed May 6, 2026 says.
Directors and officers
18
report now, of 34 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · 12.8% in Nov 5, 2025
Capital World Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock
Capital Research Global Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock · 5.4% in Feb 13, 2025
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 10% in Apr 7, 2025
What ALNY reports owning in othersstakes of 5% or more, and other ties
23 subsidiaries in 18 countries, from the list filed with the 10-K filed Feb 12, 2026.
Insider tradesForm 4
268sales
2purchases
125sales on a scheduled plan
8people selling
$36.9Msold, in dollars
$500,000bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 35 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer | 60 | $20.4M | 20 | 0 | $0 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 66 | $9.6M | 66 | 0 | $0 |
| Garg Pushkal | EVP Chief R&D | 53 | $5.4M | 31 | 0 | $0 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 40 | $3.2M | 0 | 0 | $0 |
| Tanguler Tolga | EVP, Chief Commercial Officer | 40 | $2.4M | 0 | 0 | $0 |
| Mclaughlin Melissa | Chief Human Resources Officer | 14 | $1.3M | 14 | 0 | $0 |
| Pyott David E I | director | 5 | $1.1M | 5 | 0 | $0 |
| Supran Bryan | EVP, CLO and Secretary | 1 | $400,000 | 0 | 0 | $0 |
| Schulman Amy W | director | 0 | $0 | 0 | 1 | $300,000 |
| Sigal Charles Elliott | director | 0 | $0 | 0 | 1 | $200,000 |